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Abstract Obsessive-compulsive disorder (OCD) is a chronic,
disabling disorder. Ten percent of patients remain treatment
refractory despite several treatments. For these severe,
treatment-refractory patients, repetitive transcranial magnetic
stimulation (rTMS) has been suggested as a treatment option.
Since1997,inpublishedtrials,atotalof110OCDpatientshave
been treated with rTMS. This review aims to provide an update
on rTMS treatment in patients with OCD. First, the mechanism
ofactionisdiscussed,followedbytheefficacyandsideeffects
of rTMS at various brain targets, and finally implications for
the future. Due to the lack of studies with comparable
stimulation or treatment parameters and with reliable designs,
it is difficult to draw clear conclusions. In general, rTMS
appears tobeeffective inopen-labelstudies;however, this has
not yet been replicated in randomized, sham-controlled trials.
Keywords Repetitive transcranial magnetic stimulation.
rTMS.Treatment refractory.Obsessive-compulsive
disorder.Targets
Introduction
Obsessive-compulsivedisorder(OCD) is a highly disablitating
psychiatric disorder characterized by obsessions and compul-
sions.Obsessionsareegodystonic,unwantedthoughts,images,
or impulses that repeatedly enter one’s mind. Compulsions
arerepetitive,time-consuming behaviorsormental acts often
performed to neutralize the anxiety provoked by obsessions
[1]. The prevalence of OCD in the general population is
estimated at 1% to 3%, and the disorder is associated with
impaired functioning and decreased quality of life [2, 3]. The
general treatment of OCD is a serotonin reuptake inhibitor at
an adequate dose, cognitive-behavioral therapy, or a combi-
nation of the two. However, up to 40% of patients fail to
respond satisfactorily to these generally adequate treatment
options, and 10% cannot be helped at all [1, 4].
With use of repetitive transcranial magnetic stimulation
(rTMS), it has become possible to modulate local neural
activity by inducing a depolarizing magnetic field pulse [5].
Because OCD may be related to increased neural activity in
prefrontal subcortical circuits [6], the inhibitory effect of
rTMS was hypothesized to be beneficial in OCD treatment.
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DOI 10.1007/s11920-011-0205-3In 1997, Greenberg et al. [7] introduced rTMS as a new
treatment approach for OCD. Earlier, rTMS had been shown
to have a positive effect on mood disorders with stimulation
of the prefrontal cortex [8]. Greenberg et al. [7] hypothesized
that inhibition of the prefrontal activity with rTMS might
reduce obsessive-compulsive symptoms. They applied rTMS
(80% motor threshold, 20 Hz for 2 s/min) for 20 min to 12
patients with OCD and found significantly decreased compul-
sive urges for 8 h after stimulation. Since then, rTMS has been
investigated in OCD, targeting several brain areas within the
corticostriatal network. In this article, the mechanism of action
is discussed first, then the efficacy and side effects of rTMS at
various brain targets, and finally implications for the future.
Mechanism of Action
In the early-1980s, the transcranial magnetic stimulation
(TMS) device was developed by Barker and colleagues [5].
The device stimulates the human cortex directly using a
contactless and noninvasive method. It uses a strong pulse of
electrical current that is sent through a coil to induce a
magnetic field pulse in the area under the coil. This pulse has
the capacity to depolarize superficial local neurons [5]. To
create a longer lasting effect of the depolarized neurons,
application of rTMS is needed. The magnitude and direction
of rTMS-induced neuronal modulation depend on extrinsic
factors such as motor threshold, frequency, and total number
of stimuli, and intrinsic factors such as the functional state of
the cortex [9]. For example, it appears that low-frequency
rTMS (0–5 Hz) results in decreased neural excitability and
regional cerebral blood flow, as opposed to high-frequency
rTMS (5–20 Hz), which increases both [10].
Becauseknowledgeofinvolvementofspecificbraincircuits
in OCD is advancing, rTMS has been applied to several brain
targets (Table 1). The rationale for the first rTMS studies in
OCD was based on functional neuroimaging studies of OCD
that demonstrated abnormalities in the orbitofrontal subcorti-
cal circuits, especially in the orbital frontal gyri and medial
caudate nuclei [11]. This circuitry may be manipulated with
rTMS by 1) stimulation of the dorsolateral prefrontal cortex
(DLPFC) [12], 2) inhibition of the orbitofrontal cortex
(OFC) directly [13], or 3) inhibition of the supplementary
motor area (SMA). The SMA was chosen as a useful target
for rTMS because it has extensive connections with regions
implicated in cognitive processes and motor control [14, 15].
Efficacy of Repetitive Transcranial Magnetic
Stimulation in Obsessive-Compulsive Disorder
A total of 110 OCD patients in 10 studies have been treated
with rTMS, targeting the DLPFC, the OFC, or the SMA.
Four studies investigated the efficacy of rTMS in OCD in a
double-blind, randomized, sham-controlled design [12, 16,
18￿, 19]; three studies in a sham-controlled design,
although not double-blind [13, 17￿, 20]; and three case
studies in an open fashion [7, 14, 21]. The characteristics of
each study are summarized in Table 1.
Dorsolateral Prefrontal Cortex
The DLPFC has been the most investigated target for rTMS
in OCD. In 1997, Greenberg et al. [7] treated 12 OCD
patients with rTMS to the right DLPFC, the left DLPFC,
and lastly the midoccipital cortex as a control condition [7].
Eight of 12 patients were stable on serotonin reuptake
inhibitor treatment. rTMS was randomly applied to these
targets in an open fashion on separate days, at 80%
threshold, 20 Hz for 2 s/min for 20 min. Compulsions, as
measured by the Yale-Brown Obsessive Compulsive Scale
(Y-BOCS), decreased significantly with 34.8% immediately
after right DLPFC stimulation (P<0.01) and remained
significant 8 h afterward (P<0.02), whereas obsessions
did not decrease significantly. Depressive symptoms de-
creased significantly as well, although the effect did not last
longer than 8 h. Compulsions decreased instantly with
26.8% (P<0.03) following left DLPFC stimulation, but
similar to depressive symptoms, they returned after 8 h.
Midoccipital stimulation increased compulsions, as mea-
sured by the Y-BOCS (nonsignificantly) (P=0.07).
In 2001, Sachdev et al. [21] tried to replicate this study
in 12 patients with treatment-resistant OCD. Right (n=6)
and left (n=6) DLPFC stimulation was applied in an open
fashion at 10 Hz, 100% motor threshold for 10 sessions of
2.5 min. At 4 weeks of follow-up, rTMS led to a mean
decrease on the Y-BOCS of 57% for right DLPFC and 27%
for left DLPFC. All 12 individuals were analyzed together,
as there were no differences on any of the parameters
measured, and showed a significant decrease of 42% on the
Y-BOCS at 1-month follow-up (P=0.003). However, after
corrections for depression scores on the Montgomery-
Asberg Depression Rating Scale, the significance disap-
peared (P=0.06). In the same year, the first randomized,
sham-controlled, double-blind rTMS OCD trial was com-
pleted. Alonso et al. [16] randomly assigned 18 patients
with OCD to real rTMS (n=10) or sham rTMS (n=8) at the
right DLPFC. The rTMS lasted 20 min at 1 Hz for both
conditions, but the motor threshold was 110% for real
rTMS and 20% for sham rTMS. This study failed to find
significant improvement on the Y-BOCS or Hamilton
Depression Rating Scale (HAM-D) after 18 sessions.
In 2006, this randomized, sham-controlled, double-blind
design was repeated stimulating the left instead of the right
DLPFC in 30 treatment-resistant OCD patients [19].
Patients were given 10 daily sessions of sham or real
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￿rTMS (1 Hz, 110% motor threshold) in addition to ongoing
serotonin reuptake inhibitor treatment. After 2 weeks of
follow-up, obsessive-compulsive symptoms improved, with
mean Y-BOCS reductions of 28%, but no differences
between sham and real rTMS were observed. The authors
concluded that rTMS did not result in an effect on OCD by
stimulating the left DLPFC. Similarly, in a study by
Sachdev et al. [12], high-frequency (10 Hz, 110% motor
threshold) rTMS of the left DLPFC yielded significant Y-
BOCS decreases (6.0 points, 23.1%) over 2 weeks in 10
OCD patients, but the effects were similar after sham rTMS
in 8 patients (5.0 points, 20.4%).
Finally, in an Indian sham-controlled study, active rTMS at
10 Hz, 110% motor threshold (n=21) and sham rTMS (n=
21) of the right DLPFC elicited similar improvement in
obsessions and compulsions 2 weeks after the 10th session
[20]. The Y-BOCS reduction for active rTMS was 5.0 points
(19.5%), and 4.2 points (17.7%) for sham rTMS. Interest-
ingly, depressive scores, as measured by the HAM-D, were
reduced significantly over time in the real rTMS group
compared with the sham rTMS group (P>0.04). A total of
76.2% of those receiving real rTMS were partial responders
(25% reduction in HAM-D scores from baseline), compared
with 66.7% in the sham group. The authors concluded that
right DLPFC rTMS has no effect on OCD but is modestly
effective in the treatment of comorbid depressive symptoms.
In conclusion, in open-label studies, high-frequency
rTMS of the right and/or left DLPFC appears to be
effective in reducing obsessive-compulsive symptoms.
However, this could not be replicated in double-blind,
sham-controlled studies. In those studies, neither low nor
high rTMS and neither rTMS to the left nor to the right
DLPFC appeared to be more effective than sham rTMS.
Orbitofrontal Cortex
In 2009, Ruffini and colleagues [13] examined the OFC as
a new target for rTMS in drug-resistant OCD patients. The
participants received 10 min of 1-Hz rTMS at 80% motor
threshold for 15 sessions to the left OFC; however, the coil
was placed parallel (active, n=16) or perpendicular (sham,
n=7) to the scalp. They found significant reduction of Y-
BOCS scores comparing active versus sham treatment for
10 weeks after the end of rTMS (P<0.02), with loss of
significance after 12 weeks (P<0.06). Y-BOCS reduction
was 19.7% immediately after rTMS and 14.7% after
12 weeks of follow-up, but only 6.7% and 5.7%,
respectively, for the sham condition. There was also a
benefit in terms of depressive and anxiety symptoms, but
not at a significant level in the two groups. Similar to
findings for DLPFC rTMS, this study suggests that low-
frequency rTMS of the OFC may only acutely improve
obsessive-compulsive symptoms.
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￿Supplementary Motor Area
Two groups investigated the efficacy of low rTMS to the
SMA in addition to ongoing pharmacotherapy. In 2006,
Mantovani et al. [14] conducted an open-label study of 10
patients with OCD, Tourette’s syndrome, or both. Individ-
uals were treated with active rTMS to the SMA for 10 daily
sessions at 1 Hz, 100% motor threshold. After 2 weeks of
daily rTMS, the Y-BOCS reduction (28.6%) and HAM-D
reduction (47.8%) were both significant, and they remained
stable after 3 months’ follow-up in the OCD as well as in
the OCD/Tourette’s syndrome group. In 2010, the same
group examined rTMS (at 1 Hz and 100% motor threshold)
to the SMA bilaterally in a randomized, sham-controlled,
double-blind design [18]. After 4 weeks of stimulation, the
Y-BOCS decreased significantly (P<0.001) in the active
group (6 points, 25.4%) and the sham group (3.2 points,
12.0%) without significant differences between the two
treatment conditions.
Finally, an open, sham-controlled study investigated the
possible therapeutic effects and safety of sequentially
combined low-frequency (1 Hz, 110% threshold) rTMS to
the right DLPFC and the SMA in 10 patients with
treatment-resistant OCD [17]. Similar improvements in
obsessive-compulsive and depressive symptoms were ob-
served for sham and real rTMS at 2 weeks after the last of
14 sessions. The Y-BOCS reductions were 2.9 points
(10.9%) and 3.4 points (12.9%) for real and sham rTMS,
respectively. rTMS was a safe method, and there was no
significant change in cognitive functioning after stimula-
tion. Similar to DLPFC and OFC stimulation, rTMS to the
SMAwas a safe method to immediately improve obsessive-
compulsive symptoms; however, improvement did not
linger on over time.
In conclusion, efficacy of low- and high-frequency
rTMS to the left or right DLPFC, the OFC, or the SMA
has been investigated in a total of 110 obsessive-
compulsive patients over the past decade. Although open
studies have initially demonstrated beneficial effects of
rTMS on obsessive-compulsive and depressive symptoms
during the first hours after stimulation, these effects
disappeared during follow-up and, more importantly, rTMS
did not show any advantages over sham stimulation in
double-blind, sham-controlled studies.
Side Effects and Safety
rTMS is generally regarded as a safe and noninvasive
therapeutic technique. Although extremely rare, the most
severe acute adverse effect related to rTMS is the induction
of epileptic seizures. The chance of getting a seizure during
high-frequency rTMS is greater than during low-frequency
rTMS. Other side effects that have been reported are
induction of hypomania, local pain, headache, paresthesia,
hearing changes, and thyroid-stimulating hormone and
blood lactate level changes. The two latter have only been
reported in high rTMS [22].
In the studies of rTMS in OCD patients, low-frequency
rTMS study patients occasionally reported headache or
localized scalp pain [14, 16, 17￿], whereas in the high-
frequency rTMS patients, side effects were more often
noted. The most common complaint in those studies was
headache, followed by localized scalp pain, facial nerve
stimulation, fainting, and weepiness [12, 20, 21]. None of
the side effects held on longer than 4 weeks after
stimulation, and neither serious adverse events such as
seizures and memory problems nor cognition problems
were disclosed.
Conclusions and Future Directions
Since 1997, rTMS has been applied as an experimental
treatment in cases of refractory OCD. Local induction of a
depolarizing magnetic field pulse may decrease obsessive-
compulsive symptoms by normalizing hypermetabolism in
orbitofrontal-striatal circuits. The technique is noninvasive
and yields no side effects or mild side effects, of which
headache is the most common. Because of the lack of
studies with comparable stimulation or treatment parame-
ters and with reliable designs, it is difficult to draw clear
conclusions; this corresponds with a Cochrane review from
2003 about TMS treatment in OCD [23]. Explorations of
rTMS to the DLPFC, OFC, or SMA in a total of 10 studies
have demonstrated only acute efficacy for obsessive-
compulsive symptoms of rTMS and no differences with
sham treatment.
To generalize the results of these studies, further research
is necessary. Careful consideration of target regions and
stimulation parameters, longer follow-up, and the use of a
double-blind, sham-controlled design may allow us to draw
founded conclusions in the future. Besides, as the efficacy
of rTMS is often time limited, the necessity of a second
rTMS after several weeks should be investigated. More-
over, functional MRI studies of rTMS in OCD are needed
to clarify the specific stimulation region of rTMS. Never-
theless, rTMS may play an important role in research
settings. For example, rTMS could be used to modulate
obsessive-compulsive symptoms and brain activity in
functional MRI and receptor-binding studies. Otherwise,
as the improvement of symptoms is often noted in sham
settings, it would be interesting to investigate the neural
underpinnings of the placebo effect caused by sham rTMS.
Finally, a novel stimulation paradigm was recently
designed: theta-burst stimulation, a low-intensity burst of
Curr Psychiatry Rep (2011) 13:289–294 293rTMS at 50 Hz as a safer, more consistent, and longer
lasting rTMS [24]. The results of the first case study with
this paradigm in OCD and depression are promising and
warrant further exploration [25￿].
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